Zimmer Biomet Holdings, Inc.’s Stock Price Soars to $92.17, Marking a Robust 3.40% Increase

Zimmer Biomet Holdings, Inc. (ZBH)

92.17 USD +3.03 (+3.40%) Volume: 1.8M

Zimmer Biomet Holdings, Inc.’s stock price is currently at 92.17 USD, witnessing a positive surge of +3.40% this trading session with a trading volume of 1.8M. With a year-to-date percentage change of +2.50%, ZBH’s stock performance continues to show promising growth.

Latest developments on Zimmer Biomet Holdings, Inc.

Today, Zimmer Biomet Holdings Inc. stock is outperforming its competitors on a strong trading day. Investors are questioning whether value investors should buy Zimmer Biomet (ZBH) stock, as the company’s Form 4 filing for October 12 shows activity in the surgical equipment and consumables sector. Additionally, the US98956PAB85 bond yield and price for Zimmer Biomet Holdings Inc. are also worth monitoring for potential stock price movements.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Zimmer Biomet Holdings has a positive long-term outlook. With high scores in Value and Momentum, the company is positioned well for growth and potential returns for investors. The company’s strong focus on innovation and market presence in orthopedic, dental, and spinal reconstructive implants further solidifies its outlook for the future.

Zimmer Biomet Holdings, Inc. has received favorable scores in key areas such as Value, Momentum, and Dividend. This indicates a promising outlook for the company in terms of its financial performance and stability. With a strong presence in the global market for medical equipment, Zimmer Biomet Holdings is well-positioned to continue serving patients worldwide and maintaining its resilience in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma